Status:
ACTIVE_NOT_RECRUITING
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
Lead Sponsor:
Mayo Clinic
Conditions:
Hepatitis C
Kidney Transplant; Complications
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ reci...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Listed kidney, heart, lung and/or pancreas patients who are negative for chronic hepatitis C infection
- Willing to accept and consent for accepting hepatitis C positive graft
- Exclusion criteria:
- Existing chronic liver disease (liver cirrhosis)
- Concomitant infection with HIV or Chronic hepatitis B
- Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection
- Pregnancy (Pregnant patients do not undergo solid organ transplants)
Exclusion
Key Trial Info
Start Date :
September 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04508907
Start Date
September 10 2020
End Date
November 1 2026
Last Update
December 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Phoenix, Arizona, United States, 85054